For the quarter ended September 2025, McKesson (MCK) reported revenue of $103.15 billion, up 10.1% over the same period last year. EPS came in at $9.86, compared to $7.07 in the year-ago quarter.
The reported revenue represents a surprise of -1.45% over the Zacks Consensus Estimate of $104.66 billion. With the consensus EPS estimate being $8.92, the EPS surprise was +10.54%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Prescription Technology Solutions: $1.38 billion versus the four-analyst average estimate of $1.39 billion. The reported number represents a year-over-year change of +8.8%.
- Revenue- Medical-Surgical Solutions: $2.95 billion versus $3.02 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
- Revenue- Oncology & Multispecialty: $12.04 billion versus $12.02 billion estimated by two analysts on average.
- Revenue- Other: $302 million compared to the $269 million average estimate based on two analysts.
- Revenue- North American Pharmaceutical: $86.48 billion versus $88.02 billion estimated by two analysts on average.
- Adjusted Operating Profit- Medical-Surgical Solutions: $249 million versus the four-analyst average estimate of $246.33 million.
- Adjusted Operating Profit- Prescription Technology Solutions: $261 million versus $245.96 million estimated by four analysts on average.
- Adjusted Operating Profit- Corporate: $-151 million versus the three-analyst average estimate of $-166.06 million.
- Adjusted OPERATING PROFIT- North American Pharmaceutical: $851 million versus $772.24 million estimated by two analysts on average.
- Adjusted OPERATING PROFIT- Oncology & Multispecialty: $397 million versus $356.64 million estimated by two analysts on average.
- Adjusted OPERATING PROFIT- Other: $25 million versus $13.11 million estimated by two analysts on average.
View all Key Company Metrics for McKesson here>>>
Shares of McKesson have returned +12.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
McKesson Corporation (MCK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
